Susquehanna International Group, LLP Gamida Cell Ltd. Transaction History

Susquehanna International Group, LLP

$568 Billion
Q1 2024

A detailed history of Susquehanna International Group, LLP transactions in Gamida Cell Ltd. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 67,598 shares of GMDA stock, worth $2,027. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,598

Previous 646,097 89.54%

Holding current value

$2,027

Previous $264,000 99.24%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$0.04 - $0.46 $23,139 - $266,109	-578,499 Reduced 89.54%	67,598 $2,000
Q4 2023 Feb 14, 2024	BUY	$0.25 - $1.02 $1,848 - $7,541	7,394 Added 1.16%	646,097 $264,000
Q3 2023 Nov 14, 2023	BUY	$0.85 - $1.87 $521,766 - $1.15 Million	613,843 Added 2469.2%	638,703 $657,000
Q2 2023 Aug 11, 2023	SELL	$0.73 - $2.37 $12,405 - $40,275	-16,994 Reduced 40.6%	24,860 $47,000
Q1 2023 May 16, 2023	SELL	$0.68 - $1.71 $77,581 - $195,095	-114,091 Reduced 73.16%	41,854 $33,000

Q4 2022 Feb 14, 2023	BUY	$1.15 - $2.1 $8,664 - $15,821	7,534 Added 5.08%	155,945 $201,000
Q3 2022 Nov 14, 2022	SELL	$1.53 - $3.39 $185,921 - $411,942	-121,517 Reduced 45.02%	148,411 $236,000
Q2 2022 Aug 15, 2022	BUY	$1.73 - $4.29 $326,134 - $808,737	188,517 Added 231.56%	269,928 $477,000
Q1 2022 May 16, 2022	SELL	$2.22 - $4.47 $95,229 - $191,745	-42,896 Reduced 34.51%	81,411 $338,000
Q4 2021 Feb 14, 2022	BUY	$2.2 - $4.46 $188,667 - $382,480	85,758 Added 222.46%	124,307 $316,000
Q3 2021 Nov 15, 2021	SELL	$3.85 - $6.44 $54,442 - $91,068	-14,141 Reduced 26.84%	38,549 $151,000
Q2 2021 Aug 11, 2021	BUY	$5.85 - $8.33 $308,236 - $438,907	52,690 New	52,690 $338,000

Others Institutions Holding GMDA

# of Institutions

Shares Held

11.4M

Call Options Held

235K

Put Options Held

70.5K

View Full List

About Gamida Cell Ltd.

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

More about GMDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Gamida Cell Ltd. Transaction History